New combo therapy targets tough prostate cancer

NCT ID NCT07319871

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work better. The main goals are to find the safest dose and check for side effects in about 40 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.